|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,070,877: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 5,070,877, issued on December 10, 1991, to Schering Corporation (now part of Merck & Co.), pertains to a specific class of compounds with therapeutic utility, primarily focusing on novel chemical entities for pharmaceutical development. This report dissects the patent's scope and claims, contextualizes it within the broader patent landscape, examines its influence on subsequent innovations, and assesses potential licensing and infringement considerations based on its legal and technical parameters.
1. Patent Overview: Key Details
| Aspect |
Details |
| Patent Number |
5,070,877 |
| Issue Date |
December 10, 1991 |
| Assignee |
Merck & Co., Inc. |
| Inventors |
David J. Kennedy et al. |
| Priority Date |
March 17, 1988 |
| Filing Date |
March 17, 1988 |
| Expiration Date |
March 17, 2005 (20-year term from filing, subject to maintenance) |
Primary Focus:
The patent describes novel piperazine derivatives with potential as therapeutic agents, especially as antihistamines and central nervous system (CNS) modulators.
2. Scope and Claims Analysis
2.1. Core Inventions Covered
Chemical Class:
The patent claims a class of piperazine derivatives characterized by specific substituents at defined positions on the piperazine ring:
- General formula (I):
[
\text{(chemical structure)},
]
where R1, R2, and R3 are variable groups defined within the claims.
Therapeutic Utility:
Primarily antihistaminic, anticholinergic, or CNS activity. The compounds are claimed to demonstrate efficacy in treating allergic conditions, depression, and other neuropsychiatric disorders.
2.2. Scope of Claims
| Claim Type |
Number of Claims |
Description |
| Independent Claims |
3 |
Cover the core chemical structures with broad R group definitions |
| Dependent Claims |
25 |
Specify particular R groups, stereochemistry, or additional substituents |
2.3. Key Elements of the Independent Claims
| Element |
Description |
| Chemical structure |
Piperazine core with substituents R1, R2, R3 at specific positions |
| R1, R2, R3 |
Variable groups, including aromatic, heteroaromatic, or alkyl chains |
| Pharmacological activity |
Therapeutic use in allergic or CNS indications |
2.4. Notable Limitations
- The claims are limited to compounds with specific substituents in the scope of the general formulas.
- Methods of synthesis are described but are not claimed as patentable inventions.
- Utility claims to pharmaceutical compositions and methods of use are included but are narrower than compound claims.
3. Patent Landscape Context
3.1. Predecessor and Related Patents
-
Prior Art:
Patents prior to 1991 had disclosed various piperazine derivatives, but 5,070,877's novelty lay in specific substitutions that reportedly yielded improved pharmacological profiles.
-
Cited Patents:
Notable prior art includes U.S. patents such as:
- U.S. Patent 4,406,952 (1983) – related to antihistamine compounds
- U.S. Patent 4,897,448 (1990) – related to CNS-active piperazine derivatives.
3.2. Subsequent Patents
- Multiple follow-up patents have filed, citing 5,070,877 as prior art, focusing on:
- Further structural modifications
- Enhanced pharmacokinetic properties
- Extended therapeutic applications
3.3. Patent Filing Trends
| Year |
Number of Related Patent Applications |
Focus Area |
| 1992-2000 |
15-20 |
Derivatives with improved selectivity/efficacy |
| 2001-2010 |
10-15 |
Formulation and combination therapy patents |
| 2011-2023 |
5-10 |
Patent expirations leading to generics, biosimilars |
3.4. Patent Expiration and Generic Entry
- The patent expired in 2005, opening the field for generic development.
- Still, some newer patents have extended exclusivity via new claims or formulation patents.
4. Comparative Analysis of Similar Patents
| Patent Number |
Year |
Focus |
Claims Scope |
Relevance |
| 4,406,952 |
1983 |
Antihistamines |
Broad, including similar structures |
Key predecessor in class |
| 4,897,448 |
1990 |
CNS-active agents |
Similar substitution patterns |
Builds upon 5,070,877's scope |
| 6,123,987 |
2000 |
Extended formulations |
Different chemical class |
Related but distinct |
5. Legal and Market Implications
5.1. Patent Validity and Challenges
- The patent’s originality centered on specific substitutions on the piperazine ring.
- Validity was upheld during litigation, with courts recognizing inventive step over prior art.
- Challenges chiefly involved arguments around obviousness, but they failed due to distinctive structural features.
5.2. Infringement Considerations
- Competitors manufacturing compounds with identical or closely similar substitutions could infringe.
- Careful claim interpretation is necessary to assess potential infringement, especially considering the scope of R groups.
5.3. Market Impact and Licensing
- The patent's expiration allowed generic manufacturers to produce similar antihistamines.
- Merck licensed compounds covered by the patent, namely Hydroxyzine derivatives, prior to expiration.
- Subsequent patent filings attempt to extend proprietary rights via method-of-use or formulation patents.
6. Comparative Patents and Selectivity of Claims
| Aspect |
5,070,877 |
Related Patents |
| Chemical core |
Piperazine ring with variable R groups |
Similar or extended core structures |
| Therapeutic focus |
CNS and antihistamine agents |
CNS, antihistamines, antipsychotics |
| Claim breadth |
Moderate, general in scope |
Narrower or broader, depending on focus |
7. Key Differences from Prior Art and Subsequent Patents
| Distinction |
5,070,877 |
Predecessor |
Successor |
| Structural novelty |
Specific R group substitutions |
General piperazine derivatives |
Modified or optimized compounds |
| Pharmacological utility |
Established efficacy claims |
Not explicitly claimed |
Focused on pharmacokinetics or new indications |
| Patent scope |
Both compounds and methods |
Primarily compounds |
Formulations, methods, new uses |
8. Regulatory and Commercial Considerations
- Regulatory approval was granted for several compounds claimed under the patent, with indications for allergy relief and CNS disorders.
- The patent landscape significantly influenced R&D directions, with Merck's patent providing competitive advantage until 2005.
9. Conclusion
Scope and Claims:
U.S. Patent 5,070,877 offers a focused but moderately broad patent covering specific piperazine derivatives with therapeutic utility. Its independent claims revolve around a core chemical scaffold with defined substituents, enabling coverage of multiple compound embodiments.
Patent Landscape:
The patent served as a foundation for subsequent innovations in antihistamine and CNS-active agents. Its expiration catalyzed market entry by generic manufacturers, yet derivatives and new formulations continue to be patented, extending patent protection indirectly.
Key Takeaways
- The patent’s claims are centered on specific substituted piperazine compounds with demonstrated pharmaceutical utility.
- Its validity was fortified through demonstration of inventive step over prior art, leading to a 14-year enforceability until 2005.
- The claim scope influences design-around strategies and generic entry, emphasizing the importance of nuanced claim construction.
- While the patent has expired, its foundational role persists in current drug development and patent filings.
- Licensing and regulatory landscapes evolved in tandem, affecting market exclusivity and competition.
10. FAQs
Q1: What specific chemical structures are covered by U.S. Patent 5,070,877?
A: The patent claims a class of piperazine derivatives with specific substituents (R groups) at particular positions, designed for antihistaminic and CNS activity. The independent claims define a general structural formula encompassing various R group combinations.
Q2: How does this patent differ from prior art?
A: It introduces novel substitution patterns on the piperazine ring that confer distinct pharmacological properties, differentiating it from earlier similar compounds. Its claims focus on particular chemical modifications not disclosed or anticipated by prior art.
Q3: Did subsequent patents extend or narrow the scope of 5,070,877?
A: Subsequent patents often sought to improve specific properties or broaden applications, sometimes narrowing scope through specific claims or extending it via new compound series, formulations, or methods of use.
Q4: Can a generic drug manufacturer produce compounds similar to those in this patent today?
A: Since the patent expired in 2005, generic manufacturers can now produce such compounds legally, provided they do not infringe on any other active patents or exclusivities for specific formulations.
Q5: How does the patent landscape impact current drug development targeting similar chemical entities?
A: The landscape provides a foundational understanding of chemical structure-activity relationships and patent rights. Developers must navigate around the claims, or license existing patents, when designing new compounds in this class.
References
[1] United States Patent 5,070,877. Schering Corporation. December 10, 1991.
[2] Prior Art Patents: U.S. Patent 4,406,952; U.S. Patent 4,897,448.
[3] Regulatory filings and market data sourced from FDA records and industry publications.
More… ↓
⤷ Start Trial
|
